Beckpharma acquires first products from Cuban biotech institute
Beckpharma Limited, the UK-based specialist bioscience company commercialising biopharmaceuticals and diagnostics, announced that it has signed agreements to acquire its first two products to submit for regulatory approval in Europe. The innovative products were acquired from Centro Nacional de Sanidad Agropecuaria "CENSA", a leading biotechnology institute in Cuba.
The first product is Surfacen(TM), a natural surfactant product which can be used for the 2 million premature babies around the World who are born without sufficient quantities of their own normal surfactant that is required to help inflate their lungs in order to take their first breath of life. Supplementing the levels of surfactant in the lungs of premature babies is now a common procedure however there can be problems with the existing products which Surfacen(TM) can overcome.
The second product is NewVagin(TM), a diagnostic for identifying the main causative organisms of vaginitis, a major cause of feminine healthcare problems. NewVagin(TM) can identify a range of common pathogens in a single test, which can take place in the doctor's office rather than waiting for samples to be tested in a hospital pathology laboratory. As a result of this early diagnosis, specific and appropriate therapy can be commenced sooner with considerable benefit to the patient.
This is an important milestone for Beckpharma, as it executes its strategy of acquiring established value-added products for commercialisation in Europe. Beckpharma is now preparing regulatory dossiers for each product for submission early in 2006. Since these products are already used widely in Cuba and marketed across Latin America, the Directors believe that Beckpharma should be able to generate revenues within the next 18 to 24 months from these two products and three further high value products that are in the final stages of negotiation.
Other news from the department research and development
